TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥70 years~* Idiopathic Parkinson's Disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity~* Diagnosis of Parkinson's Disease (PD) within the last 12 months and onset of symptoms within 12 months from diagnosis~* Disease stage I or II according to Hoehn and Yahr Scale~* Ability to provide written informed consent~* Patients willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures~Exclusion Criteria:~* Disease duration more than 12 months since diagnosis and/or duration of symptoms at diagnosis for more than 12 months~* Hoehn \& Yahr stage ≥3~* Atypical or secondary parkinsonism~* Patient currently on L-dopa, Dopamine Agonist (DA) or other Parkinson's Disease (PD) medication at baseline~* Centrally acting dopaminergic agents, monoamine oxidase inhibitors (MAOIs), tolcapone, budipine, neuroleptics taken within the 28 days preceding the baseline visit~* History of deep brain stimulation~* History of severe cardiac disease/heart failure in the last 3 years~* History of repeated falls~* History of sulfite sensitivity~* Arterial hypotension~* Stroke or a transient ischemic attack within the last 12 months~* Previous or current treatment with rotigotine (at any time)~* Diagnosis of dementia according to Diagnostic and Statistic Manual (DSM)-IV-Revised~* Mini Mental State Examination (MMSE) total score \<24 at screening visit~* History of psychosis~* Clinically relevant hepatic dysfunction and/or transaminase levels 5+ times higher than upper normal value~* Experimental treatments within the antecedent 3 months~* History of drug or alcohol dependency~* Poor compliance with treatment~* Inability to comply with protocol

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): 80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
- Placebo (Type: PLACEBO_COMPARATOR): 80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Feasibility of Computerized Labor Monitor (CLM) -Heart Application (HA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Laboring women refered to the maternity center in active labor (3cm dilatation and contraction)~2. Gestational age 37-42 weeks. (GA)~3. Single Fetus.~4. Subjects who understand, agreed and signed the informed consent form.~Exclusion Criteria:~1. Women with abnormal placentation (Placenta previa) -~2. Abnormal fetal presentation (Breech presentation).~3. Maternal History of HIV and/or blood transmitted Hepatitis and /or active genital Herpes.~4. Need for immediate delivery (cord prolapsed or suspected placental abruption)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postpartum Depression: Transdermal Estradiol Versus Sertraline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-45 years~* Had a baby within the last 3 months~* Experiencing depression or lasting sadness~Exclusion Criteria:~* Current use of other therapies for depression, such as antidepressants, psychotherapy, bright light therapy, and herbal remedies such as Hypericum St. John's Wort~* DSM-IV diagnoses of bipolar 1 or 2 disorder or any psychotic episode; substance abuse within last 6 months~* Previous adverse reaction to sertraline or provera~* No pediatric care: No pediatrician with whom to coordinate breastfeeding and infant care~* Use of medications for medical disorders, except for treatment of hypothyroidism or inhalers for asthma or progestin-only contraceptives~* Heavy smoking (\>10 cigarettes per day) or intent to resume heavy smoking (unless willing to cut down)~* personal history of thromboembolic event, hypercoagulability, or first degree relatives with thromboembolic events.~* Current or past personal history of breast, uterine, or ovarian cancer.~* BRCA-positive mother~* Arterial vascular disease and/or heart disease: increased risk of stroke.~* Liver disease: increased risk of biliary stones, cholestatic jaundice and benign hepatic lesions with E2 treatment.~* Diabetes~* Pregnancy~* Infants born \<32 weeks of gestation~* Imminent suicidality and/or homicidality: in need of higher level of care than is provided in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Transdermal Estradiol (Type: EXPERIMENTAL): Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains transdermal estradiol ranging in dose from 50 to 200 mcg/day
- Sertraline (Type: ACTIVE_COMPARATOR): Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The skin patch contains no active ingredients, though packaging is designed to match active patches. The capsules contain sertraline ranging in dose from 25 to 200mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains no active ingredients, though packaging is designed to match active patches.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of one of the following histologic types according to the WHO classification:~  * Angioimmunoblastic T-cell lymphoma~ * Extranodal NK/T-cell lymphoma,nasal type~ * Enteropathy-type T-cell lymphoma~ * Hepatosplenic gamma-delta T-cell lymphoma~ * Subcutaneous panniculitis-like T-cell lymphoma~ * Anaplastic large-cell lymphoma,T/null cell,primary systemic type~ * Peripheral T-cell lymphoma,not otherwise characterized~* Newly diagnosed,age 15-65 years.~* Complete work up for baseline evaluation and measurement (Appendix B)~* Patient's free written inform consent.~Exclusion Criteria:~* Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab.~* Patients who have received prior antilymphoma treatment with chemotherapy or radiotherapy~* Patients with poor performance status (PS;ECOG criteria of 3-4)(Appendix C).~* Serologic evidence of HCV and HCV RNA of chronic hepatitis.~* Serologic evidence of HBV and HBV RNA of chronic hepatitis.~* Patients with history of impaired cardiac status or myocardial infarction.~* Patients with serum creatinine \>= 1.8 mg/dl,bilirubin \>= 1.5 times upper limit of normal range,SGOT or SGPT \>= 3 times upper limit of normal range, unless due to tumor involvement.~* Patients with active uncontrolled infection,active non-malignant gastric or duodenal ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would preclude aggressive cytotoxic chemotherapy.~* Active secondary malignancy.~* Pregnant or lactating women.~* Serious medical or psychiatric illness which prevent informed consent.~* Patients who are likely to lost to follow up (eg, unwilling or difficult to return,cannot be contacted).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1 Alemtuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have had rheumatoid arthritis (RA) for at least 6 months prior to the date of signing the informed consent at screening~* Be positive for either anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum at screening~* Have active RA defined for the purpose of this study as persistent disease activity with both of the following criteria: At least 4 swollen and 4 tender joints using a 66/68 joint count. At the time of screening, one of the tender or swollen joints or both must include the non-prosthetic knee to be biopsied; and serum C-reactive protein (CRP_ ≥ 0.60 mg/dL at screening~* Have been treated with and tolerated oral methotrexate (MTX) treatment at doses from 10 mg/week to 25 mg/week inclusive, for a minimum of 3 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0~* If using nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesics (pain relievers) regularly for RA, the participant must have been on a stable dose for at least 2 weeks prior to the first administration of study agent. If not using NSAIDs or other analgesics for RA at Week 0, the participant must have not received NSAIDs or other analgesics for RA for at least 2 weeks prior to the first administration of study agent~Exclusion Criteria:~* Has inflammatory diseases other than RA~* Has a history of juvenile idiopathic arthritis (JIA)~* Has current signs or symptoms of liver or renal insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive, or uncontrolled

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-38518168 (Type: EXPERIMENTAL): JNJ-38518168 30 mg once daily for 52 weeks.
- Placebo/JNJ-38518168 (Type: PLACEBO_COMPARATOR): Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dysregulated Tyrosine Kinase Signaling in Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have newly diagnosed or relapsed leukemia.~* Patients must sign an informed consent.~* Patients will not be excluded if they are receiving chemotherapy.~* Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.~* Patients must be =\> 18 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female age between 18 and 38 years (inclusive)~* Women with a BMI under 30 kg / m2~* Diagnosis of polycystic ovary syndrome (according to criteria of Rotterdam)~* Women who want pregnancy~* Basal basal FSH levels under or equal 10 IU / l~* Infertility justify treatment with in vitro fertilization / intracytoplasmic sperm injection~* To be included in a protocol with GnRH antagonist~* Presence of both ovaries and uterus able to support embryo implantation and pregnancy~* Absence of pregnancy before starting ovarian stimulation~* Written consent~Exclusion Criteria:~* Severe male factor not allowing an in vitro fertilization / intracytoplasmic sperm injection with ejaculated sample~* Patients with low ovarian reserve~* Important endocrine-metabolic systemic diseases affecting pituitary, thyroid, adrenals, pancreas, liver or kidney~* HIV seropositivity~* To have frozen embryos from previous cycles of assisted reproduction~* Undiagnosed vaginal haemorrhage~* Poor response in previous cycles of in vitro fertilization with standard stimulation protocols~* Pregnancy, lactation or contraindication to get pregnant~* Malformations of the sexual organs incompatible with pregnancy~* History of allergy to gonadotrophin preparations or its excipients~* Alcohol, drugs or psychotropic addiction~* Concurrent participation in another study~* Previous history of severe hyperstimulation syndrome~* Concomitant medication that may interfere with the study medication: different hormonal treatments used in the study, other thyroid hormones, antipsychotics, anxiolytics, hypnotics, sedatives, chronic treatment with inhibitors of prostaglandin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Fostipur (Type: ACTIVE_COMPARATOR): None
- Meriofert (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Minocycline for HIV+ Cognitive Impairment in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection prior to study entry~* Naïve to any antiretroviral regimen and ineligible to receive antiretroviral therapy by cluster of differentiation 4 (CD4) criteria in Uganda~* Negative serum or urine pregnancy test for women of childbearing potential~* Willingness to use birth control~* Age 18-65 years~* AIDS Dementia Scale Stage 0.5 OR 1~* Impaired cognitive performance as evidenced by an International HIV Dementia Scale (HDS) as defined by the protocol~* Ability to sit or stand and swallow intact capsules with an 8-ounce glass of water~* Ability and willingness of subject or legal guardian/ representative to give written informed consent~* Resident within a 20km radius of Kampala city~Exclusion Criteria:~* Current cancers other than basal cell carcinoma, in situ carcinoma of the cervix, or Kaposi's sarcoma without evidence of visceral involvement or which does not require systemic chemotherapy~* Severe premorbid psychiatric illness, including schizophrenia and major depression which, in the in investigator's opinion, is likely to interfere with study compliance~* Active symptomatic AIDS-defining opportunistic infection within 45 days prior to study entry~* Confounding neurological disorders as defined in the protocol~* Central nervous system infections or cancers as defined in the protocol~* Systemic lupus~* Thyroid disease diagnosed within 24 weeks prior to entry~* Breastfeeding~* Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements~* Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator~* History of allergy/sensitivity to minocycline or other tetracyclines and their formulations~* Any other clinically significant condition or laboratory abnormality that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study. This includes an individual found to have an HIV dementia scale stage 3 or 4.~* Any esophageal or other condition that would interfere with the swallowing of the study medication~* Use of excluded drugs as defined by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: ACTIVE_COMPARATOR): Minocycline 100 mg orally every 12 hours
- Placebo (Type: PLACEBO_COMPARATOR): Placebo minocycline capsules every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Patient with an indication for endoscopic retrograde cholangiopancreatography~* Patient without prior endoscopic retrograde cholangiopancreatography~* Patient who accept contact by telephone~Exclusion Criteria:~* Previous sphincterotomy~* Allergy to epinephrine or indomethacin~* NSAIDs use in the prior week~* Pancreatic cancer located in the head~* Chronic pancreatitis~* Renal failure (Cr \>1.4 mg / dl)~* Indication for endotracheal intubation independent of endoscopic retrograde cholangiopancreatography~* Biliodigestive derivation~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Epinephrine sprayed on the papilla and rectal indomethacin (Type: ACTIVE_COMPARATOR): Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
- Sterile water sprayed on the papilla and rectal indomethacin (Type: PLACEBO_COMPARATOR): 10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent, release of medical information, and HIPAA forms;~2. Age greater than or equal to 18 years;~3. Male, postmenopausal female, or female who may become pregnant but is using adequate contraceptive precautions (defined as oral contraceptive, intrauterine devices, surgical contraception or a combination of a condom and a spermicide), with negative pregnancy test;~4. Admitted to the clinical center at the time of enrollment;~5. Approved and scheduled to undergo one of the following within 24 hours of enrollment:~   * Orthotopic heart transplantation~  * CABG and/or valve surgery on CPB; these patients must have an LV ejection fraction of ≤35%~  * Implantation of a pulsatile LVAD (e.g.Thoratec HeartMate® I LVAD) for destination therapy or bridge to transplantation~  * Implantation of a continuous flow LVAD (e.g. HeartMate® II, DeBakey VAD® or VentrAssist® LVAS) for destination therapy or bridge to transplantation~Exclusion Criteria:~1. History of a platelet disorder;~2. History of a known, or an inherited, or an acquired coagulation disorder in the study subject;~3. Stroke within 30 days prior to enrollment;~4. Allergy to heparin or protamine;~5. Participation in a clinical investigational intervention trial, with the exception of an investigational VAD trial, at the time of enrollment;~6. Received investigational intervention within 30 days of enrollment, with the exception of an investigational VAD trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I: Cardiopulmonary Bypass + Heart Transplantation (Type: None): CPB for orthotopic heart transplantation (excluding any patients with VADs)
- Group II: Cardiopulmonary Bypass + Pulsatile LVAD (Type: None): CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
- Group III: Cardiopulmonary Bypass + Continuous Flow LVAD (Type: None): CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
- Group IV: Cardiopulmonary Bypass + CABG Surgery (Type: None): CPB for CABG surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues